Mounjaro® Providers &
Prescriptions in Illinois
Verified Mounjaro providers across Illinois. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]
Find a Mounjaro provider in Illinois.
Every entry is checked against the NPI registry and the Illinois medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.
How a prescription works in Illinois.
You don’t have to leave Illinois to start. Because tirzepatide isn't a controlled substance, a Illinois-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you — or you can see one of the 34 local providers below in person. What you pay depends on your plan, not your zip code.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Illinois’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults — same molecule as Ozempic, higher dose.
Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist — it activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]
In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8–2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]
What the trials actually showed.
We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%) — more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Mounjaro (tirzepatide) prescribers and clinics — ordered by availability, never by who pays us.
Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover — ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.
They are the same molecule — tirzepatide, made by Eli Lilly — with different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]